Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
INMB Inmune Bio Inc
- Stocks
- Healthcare
- NASDAQ: INMB
Price (delayed)
$7.7
Market cap
$178.72M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.93
Enterprise value
$159.73M
INmune Bio, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The
Highlights
The debt has dropped by 96% year-on-year and by 10% since the previous quarter
The EPS has increased by 9% since the previous quarter
INMB's quick ratio has soared by 64% YoY but it is down by 16% QoQ
Inmune Bio's net income has decreased by 18% YoY but it has increased by 3.1% QoQ
The gross profit has shrunk by 62% YoY
The revenue has dropped by 62% year-on-year
Key stats
What are the main financial stats of INMB
Market
Valuations
Earnings
Shares outstanding
23.21M
Market cap
$178.72M
Enterprise value
$159.73M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.95
Price to sales (P/S)
3,464.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,194.6
Revenue
$50,000
Gross profit
$50,000
Operating income
-$41.52M
Net income
-$40.8M
EBIT
-$40.8M
EBITDA
-$40.8M
Free cash flow
-$32.71M
Per share
Balance sheet
Liquidity
EPS
-$1.93
EPS diluted
-$1.93
Free cash flow per share
-$1.45
Book value per share
$1.29
Revenue per share
$0
TBVPS
$0.95
Total assets
$37.8M
Total liabilities
$8.13M
Debt
$347,000
Equity
$29.67M
Working capital
$13.03M
Debt to equity
0.01
Current ratio
2.64
Quick ratio
2.44
Net debt/EBITDA
0.47
Margins
Efficiency
Dividend
EBITDA margin
-81,592%
Gross margin
100%
Net margin
-81,592%
Operating margin
-83,046%
Return on assets
-89.4%
Return on equity
-119.4%
Return on invested capital
N/A
Return on capital employed
-136.6%
Return on sales
-81,592%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
INMB stock price
How has the Inmune Bio stock price performed over time
Intraday
-0.9%
1 week
-4.47%
1 month
5.19%
1 year
-31.43%
YTD
64.88%
QTD
-1.41%
Financial performance
How have Inmune Bio's revenue and profit performed over time
Revenue
$50,000
Gross profit
$50,000
Operating income
-$41.52M
Net income
-$40.8M
Gross margin
100%
Net margin
-81,592%
The net margin has surged by 73% since the previous quarter
The operating margin has soared by 73% QoQ
The gross profit has shrunk by 62% YoY
The revenue has dropped by 62% year-on-year
Price vs fundamentals
How does INMB's price correlate with its fundamentals
Growth
What is Inmune Bio's growth rate over time
Valuation
What is Inmune Bio stock price valuation
P/E
N/A
P/B
5.95
P/S
3,464.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,194.6
The EPS has increased by 9% since the previous quarter
The P/B is 67% higher than the 5-year quarterly average of 3.6 and 43% higher than the last 4 quarters average of 4.2
INMB's equity is down by 8% since the previous quarter but it is up by 5% year-on-year
The revenue has dropped by 62% year-on-year
The price to sales (P/S) is 22% lower than the 5-year quarterly average of 4493.8 and 5% lower than the last 4 quarters average of 3690.2
Efficiency
How efficient is Inmune Bio business performance
The ROS has soared by 73% since the previous quarter
INMB's ROA has shrunk by 53% YoY
Inmune Bio's ROE has decreased by 39% YoY but it has increased by 4% from the previous quarter
Dividends
What is INMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for INMB.
Financial health
How did Inmune Bio financials performed over time
INMB's quick ratio has soared by 64% YoY but it is down by 16% QoQ
The total liabilities has shrunk by 54% YoY but it rose by 9% QoQ
The debt is 99% smaller than the equity
The debt has dropped by 96% year-on-year and by 10% since the previous quarter
The debt to equity has dropped by 96% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.